A research showed that combinatorial treatment with sarpogrelate and rosuvastatin was relatively more effective in ameliorating histopathological changes when compared to the single-drug treatment, which could effectively ameliorate HFD/STZ-induced CKD progression by improving histopathological changes in the glomerulus and tubules and attenuating interstitial fibrosis, albuminuria, and urinary cystatin C excretion. This evidence concerns the gene CST3 and chronic kidney disease.